Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye

References

• Ferrero A, Alassane S, Binquet C, Bretillon L, Acar N, Arnould L, Muselier-Mathieu A, Delcourt C, Bron AM, Creuzot-Garcher C. Dry eye disease in the elderly in a French population-based study (the montrachet study: maculopathy, optic nerve, nutrition, neurovascular and heart diseases): prevalence and associated factors. Ocul Surf. 2018;16:112–19.
   PubMed Web of Science ®Google Scholar
• Song P, Xia W, Wang M, Chang X, Wang J, Jin S, Wang J, Wei W, Rudan I. Variations of dry eye disease prevalence by age, sex and geographic characteristics in china: a systematic review and meta-analysis. J Glob Health. 2018;8:020503.
   PubMed Web of Science ®Google Scholar
• Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, Na KS, Schaumberg D, Uchino M, Vehof J, et al. Tfos dews ii epidemiology report. Ocul Surf. 2017;15(3):334–65.
   PubMed Web of Science ®Google Scholar
• Uchino M. What we know about the epidemiology of dry eye disease in japan. Invest Ophthalmol Vis Sci. 2018;59:DES1–DES6.
   PubMed Web of Science ®Google Scholar
• Alves M, Fonseca EC, Alves MF, Malki LT, Arruda GV, Reinach PS, Rocha EM. Dry eye disease treatment: a systematic review of published trials and a critical appraisal of therapeutic strategies. Ocul Surf. 2013;11:181–92.
   PubMed Web of Science ®Google Scholar
• Moshirfar M, Pierson K, Hanamaikai K, Santiago-Caban L, Muthappan V, Passi SF. Artificial tears potpourri: a literature review. Clin Ophthalmol. 2014;8:1419–33.
   PubMedGoogle Scholar
• Cutolo CA, Barabino S, Bonzano C, Traverso CE. The use of topical corticosteroids for treatment of dry eye syndrome. Ocul Immunol Inflamm. 2019;27:266–75.
   PubMed Web of Science ®Google Scholar
• Moscovici BK, Holzchuh R, Chiacchio BB, Santo RM, Shimazaki J, Hida RY. Clinical treatment of dry eye using 0.03% tacrolimus eye drops. Cornea. 2012;31:945–49.
   PubMed Web of Science ®Google Scholar
• Moscovici BK, Holzchuh R, Sakassegawa-Naves FE, Hoshino-Ruiz DR, Albers MB, Santo RM, Hida RY. Treatment of sjogren’s syndrome dry eye using 0.03% tacrolimus eye drop: prospective double-blind randomized study. Contact Lens Anterior Eye. 2015;38:373–78.
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Csa Phase 3 Study Group. Ophthalmology. 2000;107:631–39.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Van Setten G, Amrane M, Ismail D, Garrigue J-S, Figueiredo FC, Baudouin C. Efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26:287–96.
   PubMed Web of Science ®Google Scholar
• Nichols KK, Donnenfeld ED, Karpecki PM, Hovanesian JA, Raychaudhuri A, Shojaei A, Zhang S. Safety and tolerability of lifitegrast ophthalmic solution 5.0%: pooled analysis of five randomized controlled trials in dry eye disease. Eur J Ophthalmol. 2019;29:394–401.
   PubMed Web of Science ®Google Scholar
• Holland EJ, Darvish M, Nichols KK, Jones L, Karpecki PM. Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: a systematic literature review. Ocul Surf. 2019;17:412–23.
   PubMed Web of Science ®Google Scholar
• Lallemand F, Daull P, Benita S, Buggage R, Garrigue JS. Successfully improving ocular drug delivery using the cationic nanoemulsion novasorb. J Drug Deliv. 2012;2012:604204.
   PubMedGoogle Scholar
• Daull P, Lallemand F, Garrigue JS. Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. JPP. 2014;66:531–41.
   Google Scholar
• Sall KN, Cohen SM, Christensen MT, Stein JM. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye. Eye Contact Lens. 2006;32:21–26.
   PubMedGoogle Scholar
• Okanobo A, Chauhan SK, Dastjerdi MH, Kodati S, Dana R. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol. 2012;154:63–71.
   PubMed Web of Science ®Google Scholar
• Daull P, Feraille L, Barabino S, Cimbolini N, Antonelli S, Mauro V, Garrigue JS. Efficacy of a new topical cationic emulsion of cyclosporine a on dry eye clinical signs in an experimental mouse model of dry eye. Exp Eye Res. 2016;153:159–64.
   PubMed Web of Science ®Google Scholar
• Daull P, Barabino S, Feraille L, Kessal K, Docquier M, Parsadaniantz SM, Baudouin C, Garrigue JS. Modulation of inflammation-related genes in the cornea of a mouse model of dry eye upon treatment with cyclosporine eye drops. Curr Eye Res. 2019;44:476–85.
   PubMed Web of Science ®Google Scholar
• Burade V, Zalawadia R, Patel A, Ogundele A. Preclinical efficacy comparison of cyclosporine ophthalmic solution 0.09% vs cyclosporine ophthalmic emulsion 0.05% vs ciclosporin ophthalmic emulsion 0.1% in a nod mouse model of dry eye disease. Clin Ophthalmology. 2020;14:2747–55.
   PubMed Web of Science ®Google Scholar
• Daull P, Guenin S, Hamon de Almeida V, JS G. Anti-inflammatory activity of ckc-containing cationic emulsion eye drop vehicles. Mol Vis. 2018;24:459–70.
   PubMed Web of Science ®Google Scholar
• Pottel J, Armstrong D, Zou L, Fekete A, Huang XP, Torosyan H, Bednarczyk D, Whitebread S, Bhhatarai B, Liang G, et al. The activities of drug inactive ingredients on biological targets. Science. 2020;369(6502):403–13.
   PubMed Web of Science ®Google Scholar
• Said T, Dutot M, Christon R, Beaudeux JL, Martin C, Warnet JM, Rat P. Benefits and side effects of different vegetable oil vectors on apoptosis, oxidative stress, and p2x7 cell death receptor activation. Invest Ophthalmol Vis Sci. 2007;48:5000–06.
   PubMed Web of Science ®Google Scholar
• Dursun D, Wang M, Monroy D, Li DQ, Lokeshwar BL, Stern ME, Pflugfelder SC. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 2002;43:632–38.
   PubMed Web of Science ®Google Scholar
• Barabino S, Shen L, Chen L, Rashid S, Rolando M, Dana MR. The controlled-environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci. 2005;46:2766–71.
   PubMed Web of Science ®Google Scholar
• Žiniauskaitė A, Ragauskas S, Hakkarainen JJ, Rich CC, Baumgartner R, Kalesnykas G, Albers DS, Kaja S. Efficacy of trabodenoson in a mouse keratoconjunctivitis sicca (kcs) model for dry-eye syndrome. Invest Ophthalmol Vis Sci. 2018;59:3088–93.
   PubMed Web of Science ®Google Scholar
• Žiniauskaitė A, Ragauskas S, Ghosh AK, Thapa R, Roessler AE, Koulen P, Kalesnykas G, Hakkarainen JJ, Manganese(iii KS. tetrakis(1-methyl-4-pyridyl) porphyrin, a superoxide dismutase mimetic, reduces disease severity in in vitro and in vivo models for dry-eye disease. Ocul Surf. 2019;17:257–64.
   PubMed Web of Science ®Google Scholar
• Barabino S, Antonelli S, Cimbolini N, Mauro V, Bouzin M. The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye. Invest Ophthalmol Vis Sci. 2014;55:6499–504.
   PubMed Web of Science ®Google Scholar
• Lemp MA. Report of the national eye institute/industry workshop on clinical trials in dry eyes. Clao J. 1995;21:221–32.
   PubMedGoogle Scholar
• French decree n 2013-118, dated february 1, 2013, publishing the European directive 2010/63/ue. J. Offic. Rep. Fr. 2013; text 24 out of 130. 2013.
   Google Scholar
• Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, Fell HP, Ferree S, George RD, Grogan T, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317–25.
   PubMed Web of Science ®Google Scholar
• Li Z, Gong Y, Chen S, Li S, Zhang Y, Zhong H, Wang Z, Chen Y, Deng Q, Jiang Y, et al. Comparative portrayal of ocular surface microbe with and without dry eye. J Microbiol. 2019;57(11):1025–32.
   PubMed Web of Science ®Google Scholar
• Andersson J, Vogt JK, Dalgaard MD, Pedersen O, Holmgaard K, Heegaard S. Ocular surface microbiota in patients with aqueous tear-deficient dry eye. Ocul Surf. 2020;S1542-0124(20):30144–0.
   Google Scholar
• Zilliox MJ, Gange WS, Kuffel G, Mores CR, Joyce C, de Bustros P, Bouchard CS. Assessing the ocular surface microbiome in severe ocular surface diseases. Ocul Surf. 2020;18:706–12.
   PubMed Web of Science ®Google Scholar
• Baudouin C. The pathology of dry eye. Surv Ophthalmol. 2001;45:S211–220.
   PubMed Web of Science ®Google Scholar
• Bron A. The definition and classification of dry eye disease. In: Dry eye: a practical approach. Berlin, Heidelberg: Springer-Verlag; 2015. p. 1–19.
   Google Scholar
• Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli M, Ogawa Y, Perez V, et al. Tfos dews ii pathophysiology report. Ocul Surf. 2017;15(3):438–510.
   PubMed Web of Science ®Google Scholar
• Wei Y, Asbell PA. The core mechanism of dry eye disease is inflammation. Eye Contact Lens. 2014;40:248–56.
   PubMed Web of Science ®Google Scholar
• Willis KA, Postnikoff CK, Freeman A, Rezonzew G, Nichols K, Gaggar A, Lal CV. The closed eye harbours a unique microbiome in dry eye disease. Sci Rep. 2020;10:12035.
   PubMed Web of Science ®Google Scholar
• de Paiva CS, Pflugfelder SC, Ng SM, Akpek EK. Topical cyclosporine a therapy for dry eye syndrome. Cochrane Database Syst Rev. 2019;9:CD010051.
   PubMed Web of Science ®Google Scholar
• Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54:321–38.
   PubMed Web of Science ®Google Scholar
• Hwang SB, Park JH, Kang SS, Kang DH, Lee JH, Oh SJ, Lee JY, Kim JY, Tchah H. Protective effects of cyclosporine a emulsion versus cyclosporine a cationic emulsion against desiccation stress in human corneal epithelial cells. Cornea. 2020;39:508–13.
   PubMed Web of Science ®Google Scholar
• Olafsson J, ØA U, Chen X, Olafsson S, Raeder S, Dartt DA, Tashbayev B, Utheim TP. Changes in signs and symptoms of dry eye disease after using 0.1% or 0.05% emulsions of cyclosporine a eye drops. Invest Ophthalmol Vis Sci. 2018;59:912–912.
   Web of Science ®Google Scholar
• Baudouin C, de la Maza MS, Amrane M, Garrigue JS, Ismail D, Figueiredo FC, Leonardi A. One-year efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. 2017;27:678–85.
   PubMed Web of Science ®Google Scholar
• Daull P, Lallemand F, Philips B, Lambert G, Buggage R, Garrigue JS. Distribution of cyclosporine a in ocular tissues after topical administration of cyclosporine a cationic emulsions to pigmented rabbits. Cornea. 2013;32:345–54.
   PubMed Web of Science ®Google Scholar
• Daull P, Feraille L, Elena PP, Garrigue JS. Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping. J Ocul Pharmacol Ther. 2016;32:109–18.
   PubMed Web of Science ®Google Scholar